Kestra Medical Technologies (KMTS) vs Pulse Biosciences (PLSE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Pulse Biosciences (PLSE) has outperformed Kestra Medical Technologies (KMTS) over the past year, gaining 150.7% versus a gain of 7.4%. Pulse Biosciences is the larger company by market cap ($3.56 billion vs $1.53 billion), about 2.3 times the size. Kestra Medical Technologies converts more of its revenue into profit, with a net margin of -138.4% versus -20794.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KMTS | PLSE |
|---|---|---|
| Share price | $25.77 | $49.98 |
| Market cap | $1.53B | $3.56B |
| 1-day change | -2.72% | +1.81% |
| YTD return | -2.83% | +264.02% |
| 1-year return | +7.37% | +150.65% |
| 5-year return | — | +130.85% |
| EPS (TTM) | $-2.67 | $-1.18 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $95.13M | $350.00K |
| Revenue growth (YoY) | +59.03% | — |
| Net income (latest FY) | $-131.61M | $-72.78M |
| Gross margin | 51.37% | -54.00% |
| Operating margin | -141.64% | -21982.57% |
| Net margin | -138.36% | -20794.57% |
| 52-week high | $30.00 | $58.90 |
| 52-week low | $17.34 | $12.56 |
| Distance from 52-week high | -14.10% | -15.14% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +17.54% | +13.05% |
| Average volume | 357.86K | 502.81K |
| Shares outstanding | 59.56M | 71.32M |
| Employees | 443 | 116 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Pulse Biosciences is about 2.3 times larger than Kestra Medical Technologies by market value ($3.56B vs $1.53B).
- PLSE has outperformed KMTS by 143.3 percentage points over the past year.
- Kestra Medical Technologies is more profitable, keeping -138.4 cents of every revenue dollar as net income versus -20794.6 cents for Pulse Biosciences.
About Kestra Medical Technologies
KMTS stock →Kestra Medical Technologies, Ltd. operates as a wearable medical device and digital healthcare company.
Health Care · Medical/Dental Instruments · 443 employees
About Pulse Biosciences
PLSE stock →Pulse Biosciences, Inc. operates as a novel bioelectric medicine company.
Health Care · Medical/Dental Instruments · 116 employees
KMTS vs PLSE FAQ
Which is bigger, Kestra Medical Technologies or Pulse Biosciences?
Pulse Biosciences (PLSE) is larger, with a market capitalization of $3.56B compared with $1.53B for Kestra Medical Technologies (KMTS).
Which stock has performed better over the past year, KMTS or PLSE?
PLSE returned +150.65% over the past 12 months, compared with +7.37% for KMTS (price return, excluding dividends). Past performance does not predict future results.
Are Kestra Medical Technologies and Pulse Biosciences in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.